{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Radiotherapy and Immune Checkpoint Inhibitor in Metastatic Esophageal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to receive either RT combined with ICI or standard care."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were patients with metastatic esophageal cancer."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either RT combined with ICI or standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the effects of combining RT with ICI in patients with metastatic esophageal cancer."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of severe thrombocytopenia, measured over a 6-month period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the intervention group, 98 participants were analysed using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The intervention group experienced a higher incidence of severe thrombocytopenia compared to the control group."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the intervention group, with 3% experiencing severe thrombocytopenia."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided."
      },
      "Funding": {
        "score": 1,
        "evidence": "Supported by Chongqing Hospital of Traditional Chinese Medicine."
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}